Pharmaceutical - Johnson & Johnson, Amgen

Filter

Current filters:

Johnson & JohnsonAmgen

Popular Filters

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Four new drugs will change prostate cancer care, says US expert

19-02-2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer…

AlgetaAlpharadinAmgenBavarian NordicBayerJohnson & JohnsonOncologyPharmaceuticalProstvacXgevaZytiga

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

Back to top